Search for content, post, videos
Advertisement

Oasmia gets FDA approval for veterinary drug

The U.S. Food and Drug Administration (FDA) has conditionally approved the Swedish pharmaceutical company’s product Paccal.

Paccal Vet-CA1 is the first veterinary drug to utilize paclitaxel, a frequently used chemotherapeutics for the treatment of a wide range of cancers in humans. Paccal Vet-CA1 is specifically formulated for use in dogs for the treatment of canine skin and mammary cancers.

“The conditional approval of Paccal Vet-CA1 is a big step forward for veterinary cancer treatment,” commented Julian Aleksov, chief executive officer of Oasmia, in a press release. “In addition, it confirms the potential of our unique patented drug delivery technology XR-17 – a novel derivative of vitamin A that we will be using in clinical trials with our other compounds for a number of human and veterinary indications. This also improves the possibilities to secure the company’s long-term financing.”

Furthermore, Oasmia has signed an agreement with the global health care company Abbott which gives its Animal Health division the exclusive worldwide distribution rights to Paccal Vet-CA1, excluding Russia, Japan and the Commonwealth of Independent States (CIS).

Advertisement